Correlations of lysyl oxidase with MMP2/MMP9 expression and its prognostic value in non-small cell lung cancer

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 9, 2014, Pages 6040-6047

  Liu, Juan ^a   Ping, Wei ^b   Zu, Yukun ^b   Sun, Wei ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

ECM; LOX; NSCLC; Prognosis

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; MMP2 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; PROTEIN LYSINE 6 OXIDASE; TUMOR MARKER;

AGED; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; FEMALE; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; SECONDARY; TIME FACTOR; TUMOR VOLUME; UPREGULATION;

AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROTEIN-LYSINE 6-OXIDASE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; RNA, MESSENGER; TIME FACTORS; TUMOR BURDEN; UP-REGULATION;

EID: 84911888437     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Siegel R, Ward E, Brawley O and Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A and Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-241.
3. Gribben J, Rosenwald A, Gascoyne R and Lenz G. Targeting the microenvironment. Leuk Lymphoma 2010; 51 Suppl 1: 34-40.
4. Deep G and Agarwal R. Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy. Curr Cancer Drug Targets 2013; 13: 486-499.
5. Cox TR and Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Dis Model Mech 2011; 4: 165-178.
6. Lu P, Weaver VM and Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012; 196: 395-406.
7. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, Yamauchi M, Gasser DL and Weaver VM. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009; 139: 891-906.
8. Barker HE, Cox TR and Erler JT. The rationale for targeting the LOX family in cancer. Nat Rev Cancer 2012; 12: 540-552.
9. Rodriguez C, Rodriguez-Sinovas A and Martinez-Gonzalez J. Lysyl oxidase as a potential therapeutic target. Drug News Perspect 2008; 21: 218-224.
10. Maki JM. Lysyl oxidases in mammalian development and certain pathological conditions. Histol Histopathol 2009; 24: 651-660.
11. Payne SL, Hendrix MJ and Kirschmann DA. Paradoxical roles for lysyl oxidases in cancer-a prospect. J Cell Biochem 2007; 101: 1338-1354.
12. Baker AM, Cox TR, Bird D, Lang G, Murray GI, Sun XF, Southall SM, Wilson JR and Erler JT. The role of lysyl oxidase in SRC-dependent proliferation and metastasis of colorectal cancer. J Natl Cancer Inst 2011; 103: 407-424.
13. Gao Y, Xiao Q, Ma H, Li L, Liu J, Feng Y, Fang Z, Wu J, Han X, Zhang J, Sun Y, Wu G, Padera R, Chen H, Wong KK, Ge G and Ji H. LKB1 inhibits lung cancer progression through lysyl oxidase and extracellular matrix remodeling. Proc Natl Acad Sci U S A 2010; 107: 18892-18897.
14. Kessenbrock K, Plaks V and Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141: 52-67.
15. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT and Giaccia AJ. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009; 15: 35-44.
16. Ping W, Jiang WY, Chen WS, Sun W and Fu XN. Expression and significance of hypoxia inducible factor-1alpha and lysyl oxidase in non-small cell lung cancer. Asian Pac J Cancer Prev 2013; 14: 3613-3618.
17. Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, Gatter KC and Harris AL. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001; 85: 881-890.
18. Swinson DE, Jones JL, Cox G, Richardson D, Harris AL and O'Byrne KJ. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer 2004; 111: 43-50.
19. Wong CC, Zhang H, Gilkes DM, Chen J, Wei H, Chaturvedi P, Hubbi ME and Semenza GL. Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl) 2012; 90: 803-815.
20. Ji F, Wang Y, Qiu L, Li S, Zhu J, Liang Z, Wan Y and Di W. Hypoxia inducible factor 1alpha-mediated LOX expression correlates with migration and invasion in epithelial ovarian cancer. Int J Oncol 2013; 42: 1578-1588.
21. Zhang Q, Jin XS, Yang ZY, Wei M, Zhu XC, Wang P, Liu BY and Gu QL. Upregulated expression of LOX is a novel independent prognostic marker of worse outcome in gastric cancer patients after curative surgery. Oncol Lett 2013; 5: 896-902.
22. Albinger-Hegyi A, Stoeckli SJ, Schmid S, Storz M, Iotzova G, Probst-Hensch NM, Rehrauer H, Tinguely M, Moch H and Hegyi I. Lysyl oxidase expression is an independent marker of prognosis and a predictor of lymph node metastasis in oral and oropharyngeal squamous cell carcinoma (OSCC). Int J Cancer 2010; 126: 2653-2662.
23. Wilgus ML, Borczuk AC, Stoopler M, Ginsburg M, Gorenstein L, Sonett JR and Powell CA. Lysyl oxidase: a lung adenocarcinoma biomarker of invasion and survival. Cancer 2011; 117: 2186-2191.
24. Sakai M, Kato H, Sano A, Tanaka N, Inose T, Kimura H, Sohda M, Nakajima M and Kuwano H. Expression of lysyl oxidase is correlated with lymph node metastasis and poor prognosis in esophageal squamous cell carcinoma. Ann Surg Oncol 2009; 16: 2494-2501.
25. Giampuzzi M, Botti G, Cilli M, Gusmano R, Borel A, Sommer P and Di Donato A. Down-regulation of lysyl oxidase-induced tumorigenic transformation in NRK-49F cells characterized by constitutive activation of ras proto-oncogene. J Biol Chem 2001; 276: 29226-29232.
26. Bouez C, Reynaud C, Noblesse E, Thepot A, Gleyzal C, Kanitakis J, Perrier E, Damour O and Sommer P. The lysyl oxidase LOX is absent in basal and squamous cell carcinomas and its knockdown induces an invading phenotype in a skin equivalent model. Clin Cancer Res 2006; 12: 1463-1469.
27. Kagan HM and Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003; 88: 660-672.
28. Palamakumbura AH, Jeay S, Guo Y, Pischon N, Sommer P, Sonenshein GE and Trackman PC. The propeptide domain of lysyl oxidase induces phenotypic reversion of ras-transformed cells. J Biol Chem 2004; 279: 40593-40600.
29. Wu M, Min C, Wang X, Yu Z, Kirsch KH, Trackman PC and Sonenshein GE. Repression of BCL2 by the tumor suppressor activity of the lysyl oxidase propeptide inhibits transformed phenotype of lung and pancreatic cancer cells. Cancer Res 2007; 67: 6278-6285.
30. Yang X, Li S, Li W, Chen J, Xiao X, Wang Y, Yan G and Chen L. Inactivation of lysyl oxidase by beta-aminopropionitrile inhibits hypoxia-induced invasion and migration of cervical cancer cells. Oncol Rep 2013; 29: 541-548.